Abstract

Longitudinal bone growth, achieved through endochondral ossification, is accomplished by a cartilaginous structure, the physis or growth plate, comprised of morphologically distinct zones related to chondrocyte function: resting, proliferating and hypertrophic zones. The resting zone is a stem cell-rich region that gives rise to the growth plate, and exhibits regenerative capabilities in response to injury. We discovered a FoxA2+group of long-term skeletal stem cells, situated at the top of resting zone, adjacent the secondary ossification center, distinct from the previously characterized PTHrP+ stem cells. Compared to PTHrP+ cells, FoxA2+ cells exhibit higher clonogenicity and longevity. FoxA2+ cells exhibit dual osteo-chondro-progenitor activity during early postnatal development (P0-P28) and chondrogenic potential beyond P28. When the growth plate is injured, FoxA2+ cells expand in response to trauma, and produce physeal cartilage for growth plate tissue regeneration.

The growth plate cartilage supports long bone growth. Here the authors identify FoxA2+ long term stem cells in the growth plate that are stratified with short term PTHrP+ cells, participate in production of hyaline cartilage, expand in response to trauma, and whose ablation impairs cartilage regeneration.

Details

Title
A FoxA2+ long-term stem cell population is necessary for growth plate cartilage regeneration after injury
Author
Shanmugam, Muruganandan 1   VIAFID ORCID Logo  ; Pierce, Rachel 1 ; Teguh, Dian Astari 2   VIAFID ORCID Logo  ; Perez Rocio Fuente 3 ; Bell, Nicole 4 ; Nguyen, Brandon 5 ; Hohl, Katherine 6   VIAFID ORCID Logo  ; Snyder, Brian D 7 ; Grinstaff, Mark W 8   VIAFID ORCID Logo  ; Alberico Hannah 1 ; Woods, Dori 1 ; Kong Yiwei 1 ; Sima Corneliu 9   VIAFID ORCID Logo  ; Bhagat Sanket 10   VIAFID ORCID Logo  ; Ho Kailing 11 ; Rosen, Vicki 11   VIAFID ORCID Logo  ; Gamer, Laura 11 ; Ionescu, Andreia M 1   VIAFID ORCID Logo 

 134 Mugar Life Sciences Building, Northeastern University, Department of Biology, Boston, USA (GRID:grid.261112.7) (ISNI:0000 0001 2173 3359) 
 Beth Israel Deaconess Medical Center, Centre for Advanced Orthopedic Studies, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547) 
 University of Oviedo, Division of Pediatrics, Oviedo, Spain (GRID:grid.10863.3c) (ISNI:0000 0001 2164 6351) 
 New York University College of Dentistry, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753) 
 Moderna Therapeutics, Ohio, USA (GRID:grid.479574.c) (ISNI:0000 0004 1791 3172) 
 Beth Israel Deaconess Medical Center, Centre for Advanced Orthopedic Studies, Boston, USA (GRID:grid.239395.7) (ISNI:0000 0000 9011 8547); Chemistry, and Medicine, Boston University, Departments of Biomedical Engineering, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558) 
 Boston Children’s Hospital, Department of Orthopedic Surgery, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438) 
 Chemistry, and Medicine, Boston University, Departments of Biomedical Engineering, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558) 
 Infection, and Immunity, Harvard School of Dental Medicine, Department of Oral Medicine, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
10  Ultragenyx Pharmaceutical, Cambridge, USA (GRID:grid.430528.8) (ISNI:0000 0004 6010 2551) 
11  Harvard School of Dental Medicine, Department of Developmental Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2660202762
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.